Van Strum & Towne Inc. Buys New Holdings in Boston Scientific Corporation $BSX

Van Strum & Towne Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 40,705 shares of the medical equipment provider’s stock, valued at approximately $1,777,000.

Several other large investors have also made changes to their positions in the company. BlackRock Inc. bought a new position in Boston Scientific in the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific during the second quarter worth $2,156,233,000. Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Amundi lifted its stake in Boston Scientific by 13.8% during the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after purchasing an additional 1,707,754 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after purchasing an additional 2,856,040 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $44.22 on Friday. The firm’s fifty day moving average price is $44.05 and its two-hundred day moving average price is $54.75. The stock has a market cap of $64.10 billion, a PE ratio of 18.74, a PEG ratio of 1.34 and a beta of 0.60. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period last year, the company earned $0.75 earnings per share. The business’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on BSX. Needham & Company LLC decreased their price target on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. TD Cowen downgraded Boston Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $56.00 to $46.00 in a research report on Friday, October 30th. Stifel Nicolaus reduced their price objective on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Wells Fargo & Company decreased their target price on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Finally, Raymond James Financial reissued an “outperform” rating and set a $57.00 target price (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.